Pub Date : 2020-01-01DOI: 10.17925/USOR.2020.13.2.73
J. Pastor
This review article summarizes the experience of the Retina Group at the Institute for Applied Ophthalmobiology, University of Valladolid, Spain. Different perfluorocarbon liquids used in intraocular surgery are discussed, as they have caused hundreds of cases of irreversible blindness in many countries since 2013. The possible causes are examined, and consideration is given to the current status and the measures that should be taken to prevent these situations from occurring in the future. Among these are: a greater awareness among ophthalmologists so they report suspected cases to their respective health agencies (medical devices office), without fear of legal reprisals by either government agencies or patients; a closer collaboration between expert clinicians and manufacturers on committees for the International Organization for Standardization in order to regulate each product individually; and the conducting of appropriate chemical and biological tests to guarantee the safety of the products.
{"title":"The Safety of Medical Devices Used During Intraocular Surgery","authors":"J. Pastor","doi":"10.17925/USOR.2020.13.2.73","DOIUrl":"https://doi.org/10.17925/USOR.2020.13.2.73","url":null,"abstract":"This review article summarizes the experience of the Retina Group at the Institute for Applied Ophthalmobiology, University of Valladolid, Spain. Different perfluorocarbon liquids used in intraocular surgery are discussed, as they have caused hundreds of cases of irreversible blindness in many countries since 2013. The possible causes are examined, and consideration is given to the current status and the measures that should be taken to prevent these situations from occurring in the future. Among these are: a greater awareness among ophthalmologists so they report suspected cases to their respective health agencies (medical devices office), without fear of legal reprisals by either government agencies or patients; a closer collaboration between expert clinicians and manufacturers on committees for the International Organization for Standardization in order to regulate each product individually; and the conducting of appropriate chemical and biological tests to guarantee the safety of the products.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"13 1","pages":"73"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/usor.2020.13.1.12
D. Vanderveen
{"title":"Orthokeratology for the Prevention of Myopic Progression in Children","authors":"D. Vanderveen","doi":"10.17925/usor.2020.13.1.12","DOIUrl":"https://doi.org/10.17925/usor.2020.13.1.12","url":null,"abstract":"<p />","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"13 1","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/USOR.2020.13.2.61
J. Pelletier
{"title":"Expanding the Role of Povidone-iodine in a COVID-19 Era","authors":"J. Pelletier","doi":"10.17925/USOR.2020.13.2.61","DOIUrl":"https://doi.org/10.17925/USOR.2020.13.2.61","url":null,"abstract":"<p />","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/usor.2020.13.1.18
C. Matossian
Following cataract surgery, patients are typically prescribed antibiotic, non-steroidal anti-inflammatory drug and corticosteroid eyedrops, each of which may be administered with a different frequency. However, patient noncompliance with prescribed eyedrop treatment is prevalent and may lead to a less than ideal outcome, with potential complications such as infection or inflammation. Numerous studies have been conducted to evaluate the extent of patient noncompliance and to identify contributing factors. The majority of these studies have focused on patients with glaucoma, because it is a chronic disease requiring lifelong use of eyedrops. Patients who have undergone cataract surgery may face greater challenges with drop instillation than glaucoma patients because of limited experience with eyedrops prior to surgery. Additionally, cataracts most often affect older persons, in whom physical or cognitive limitations may further impede successful eyedrop administration. New methods of drug delivery that bypass patient compliance are currently available. They include surgery with fewer drops as well as medication delivery systems injected or deposited into ocular structures perioperatively. These drug delivery methods not only reduce topical drop administration, but have supplanted eyedrop use in many countries. Alternative drug delivery systems are increasingly being adopted in the USA.
{"title":"Noncompliance with Prescribed Eyedrop Regimens Among Patients Undergoing Cataract Surgery—Prevalence, Consequences, and Solutions","authors":"C. Matossian","doi":"10.17925/usor.2020.13.1.18","DOIUrl":"https://doi.org/10.17925/usor.2020.13.1.18","url":null,"abstract":"Following cataract surgery, patients are typically prescribed antibiotic, non-steroidal anti-inflammatory drug and corticosteroid eyedrops, each of which may be administered with a different frequency. However, patient noncompliance with prescribed eyedrop treatment is prevalent and may lead to a less than ideal outcome, with potential complications such as infection or inflammation. Numerous studies have been conducted to evaluate the extent of patient noncompliance and to identify contributing factors. The majority of these studies have focused on patients with glaucoma, because it is a chronic disease requiring lifelong use of eyedrops. Patients who have undergone cataract surgery may face greater challenges with drop instillation than glaucoma patients because of limited experience with eyedrops prior to surgery. Additionally, cataracts most often affect older persons, in whom physical or cognitive limitations may further impede successful eyedrop administration. New methods of drug delivery that bypass patient compliance are currently available. They include surgery with fewer drops as well as medication delivery systems injected or deposited into ocular structures perioperatively. These drug delivery methods not only reduce topical drop administration, but have supplanted eyedrop use in many countries. Alternative drug delivery systems are increasingly being adopted in the USA.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"86 1","pages":"18"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/usor.2020.13.1.34
Hannah J. Yu, A. Schefler
{"title":"Radiation Retinopathy—A Review of Past and Current Treatment Strategies","authors":"Hannah J. Yu, A. Schefler","doi":"10.17925/usor.2020.13.1.34","DOIUrl":"https://doi.org/10.17925/usor.2020.13.1.34","url":null,"abstract":"<p />","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"13 1","pages":"34"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/USOR.2020.13.2.55
F. Hafezi
Corneal cross-linking (CXL) is a procedure that combines stromal riboflavin saturation and ultraviolet (UV) light to strengthen the cornea. CXL is typically performed in an operating room. The UV-riboflavin photochemical reaction also kills pathogens, and CXL is even used to treat infectious keratitis, raising the question: do you need to perform CXL in a sterile operating room? There is a trend to move small surgical procedures out of the operating room and into minor procedure rooms or the doctor’s office, and CXL is an obvious candidate for this. The benefits of avoiding the operating room in terms of cost and resource use are manifest. However, traditional CXL involves the patient lying supine for 30 minutes, while UV irradiation is applied. For CXL to be performed at, for example, the near-ubiquitous slit lamp in an office setting, several hurdles needed to be cleared, including reducing the time a patient needs to sit at the slit lamp, and understanding whether or not riboflavin settles under gravity when a patient is sat upright during CXL. This article reviews those potential obstacles and how they have been overcome, and the benefits of bringing CXL technology to clinics that do not have easy access to operating rooms for the treatment of corneal ectasia and infectious keratitis, in both developing and developed countries.
{"title":"Cross-linking at the Slit Lamp—Why Moving Corneal Cross-linking from the Operating Room to an Office-based Procedure Makes a Difference","authors":"F. Hafezi","doi":"10.17925/USOR.2020.13.2.55","DOIUrl":"https://doi.org/10.17925/USOR.2020.13.2.55","url":null,"abstract":"Corneal cross-linking (CXL) is a procedure that combines stromal riboflavin saturation and ultraviolet (UV) light to strengthen the cornea. CXL is typically performed in an operating room. The UV-riboflavin photochemical reaction also kills pathogens, and CXL is even used to treat infectious keratitis, raising the question: do you need to perform CXL in a sterile operating room? There is a trend to move small surgical procedures out of the operating room and into minor procedure rooms or the doctor’s office, and CXL is an obvious candidate for this. The benefits of avoiding the operating room in terms of cost and resource use are manifest. However, traditional CXL involves the patient lying supine for 30 minutes, while UV irradiation is applied. For CXL to be performed at, for example, the near-ubiquitous slit lamp in an office setting, several hurdles needed to be cleared, including reducing the time a patient needs to sit at the slit lamp, and understanding whether or not riboflavin settles under gravity when a patient is sat upright during CXL. This article reviews those potential obstacles and how they have been overcome, and the benefits of bringing CXL technology to clinics that do not have easy access to operating rooms for the treatment of corneal ectasia and infectious keratitis, in both developing and developed countries.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"13 1","pages":"55"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/USOR.2020.13.2.63
Omotayo A. Arowojolu, Sanja G Cypen, J. Tao
{"title":"Clinical Features and Management of Eyelid Malignancies","authors":"Omotayo A. Arowojolu, Sanja G Cypen, J. Tao","doi":"10.17925/USOR.2020.13.2.63","DOIUrl":"https://doi.org/10.17925/USOR.2020.13.2.63","url":null,"abstract":"<p />","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"13 1","pages":"63"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.17925/usor.2020.13.1.16
A. Wilkins
{"title":"Response to “Optical Lens Tinting—A Review of its Functional Mechanism, Efficacy, and Applications”","authors":"A. Wilkins","doi":"10.17925/usor.2020.13.1.16","DOIUrl":"https://doi.org/10.17925/usor.2020.13.1.16","url":null,"abstract":"<p />","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：